8-K current report · filed Oct 27, 2026

Beta Bionics, Inc. (BBNX) 8-K Current Report: October 27, 2026

Item 2.02Item EX-99.1BBNX overview

Short answer

Beta Bionics, Inc. (BBNX) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter results for period ended September 30, 2026 announced.

Beta Bionics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter results for period ended September 30, 2026 announced
  • Press release contains the company’s financial performance details and management commentary

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $35.5M, up 30% YoY, driven by PBP sales of $13.6M, up 118%
  • Gross margin 57.3%, while operating loss widened to $26.6M and adjusted EBITDA loss to $18.9M
  • Cash, equivalents and investments $373.6M; public offering added approximately $161.3M net proceeds
  • 2026 revenue guidance raised to approximately $124M-$126M, despite potential fourth-quarter deferrals of up to $8.5M
  • FDA clearance for Mint supports planned U.S. launch in Q1 2027, while 3D Intelligence resubmission targets mid-Q4 2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Beta Bionics, Inc. 8-K filings

Get the next BBNX 8-K as it lands

Follow BBNX for push alerts, or ask the research agent what this filing means.